AnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co.
AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price decreased by equities research analysts at JPMorgan Chase & Co. from $66.00 to $36.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of […]
More Stories
ProShares UltraShort Bloomberg Crude Oil (NYSEARCA:SCO) Stock Price Pass Above 200-Day Moving Average – What’s Next?
ProShares UltraShort Bloomberg Crude Oil (NYSEARCA:SCO – Get Free Report)’s stock price passed above its 200-day moving average during trading...
IP Group (LON:IPO) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
IP Group Plc (LON:IPO – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The...
Bahamas Petroleum (LON:BPC) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?
Shares of Bahamas Petroleum Company plc (LON:BPC – Get Free Report) passed above its 200-day moving average during trading on...
Geospace Technologies (NASDAQ:GEOS) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?
Geospace Technologies Co. (NASDAQ:GEOS – Get Free Report)’s share price passed above its 200-day moving average during trading on Tuesday...
Software Aktiengesellschaft (OTCMKTS:STWRY) Share Price Passes Above 200-Day Moving Average – Time to Sell?
Software Aktiengesellschaft (OTCMKTS:STWRY – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock...
FDA Overhauls ‘Healthy’ Food Label Definition
By Chase Smith The U.S. Food and Drug Administration (FDA) announced a final rule for significant updates to the definition...